1. Conformational adaptation in drug–target interactions and residence time. (September 2011) Authors: Copeland, Robert A Journal: Future medicinal chemistry Issue: Volume 3:Number 12(2011) Page Start: 1491 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Drug–target interaction kinetics: underutilized in drug optimization?. (December 2016) Authors: Copeland, Robert A Journal: Future medicinal chemistry Issue: Volume 8:Number 18(2016) Page Start: 2173 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study. Issue 5 (May 2018) Authors: Italiano, Antoine; Soria, Jean-Charles; Toulmonde, Maud; Michot, Jean-Marie; Lucchesi, Carlo; Varga, Andrea; Coindre, Jean-Michel; Blakemore, Stephen J; Clawson, Alicia; Suttle, Benjamin; McDonald, Alice A; Woodruff, Mark; Ribich, Scott; Hedrick, Eric; Keilhack, Heike; Thomson, Blythe; Owa, Takas... Journal: Lancet oncology Issue: Volume 19:Issue 5(2018) Page Start: 649 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗